BCL-XL knockdown using siRNA (siBCL-XL) significantly increased apoptosis induction (Fig. 4d) and decreased viability of ALK-rearranged lung cancer cells, compared to those treated with alectinib alone (Fig. 4e). This evidence concerns the gene ALK and lung carcinoma.